Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?

18 Oct 2012

Abstract excerpt

abstract Learning Objectives: After completing this course, the reader will be able to: Describe the oncogenic drivers in DLBCL, especially those that have recently been identified, and how they relate to the oncogenic DLBCL subtypes.Describe the prognostic and potentially predictive implications of DLBCL COO subtype for chemotherapy and rituximab.Outline the evidence for novel targeted therapies and therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23086691
DOI: 10.1634/theoncologist.2012-0218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?PMID 23086691Read ↗

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapySemantic proximity Read ↗

Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?Semantic proximity Read ↗

Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular PhenotypeSemantic proximity Read ↗

Molecular classification and therapeutics in diffuse large B-cell lymphomaSemantic proximity Read ↗

Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.Semantic proximity Read ↗

Diffuse large B-cell lymphoma.Semantic proximity Read ↗

Primary bone diffuse large B-cell lymphoma (PB-DLBCL): a distinct extranodal lymphoma of germinal centre origin, with a common EZB-like mutational profile and good prognosis.Semantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Molecular complexity of diffuse large B-cell lymphoma: a molecular perspective and therapeutic implications.Semantic proximity Read ↗

Primary Bone Diffuse Large B-cell Lymphoma (PB-DLBCL) – a distinct extranodal lymphoma of germinal center origin, with an EZB-like mutational profile and good prognosisSemantic proximity Read ↗

Biological heterogeneity in diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.